Prävention der Post-ERCP-Pankreatitis: Wie können wir sie vermeiden?

T. Rabenstein

doi:10.1055/s-0032-1330644

Endoskopie heute, Table of Contents

Endoskopie heute 2013; 26(1): 56-58
DOI: 10.1055/s-0032-1330644

Originalarbeit

Prävention der Post-ERCP-Pankreatitis: Wie können wir sie vermeiden?

Prevention of Post-ERCP Pancreatitis: How Can We Avoid It?

Authors

T. Rabenstein

Abstract

Zusammenfassung:

Die ERCP ist eine der invasivsten endoskopischen Untersuchungstechniken mit einer Komplikationsrate von bis zu 10 %. Es dominiert die Post-ERCP-Pankreatitis. Die Möglichkeiten zur Vermeidung der Post-ERCP-Pankreatitis, insbesondere NSAR und Pankreas-Stents, werden dargestellt.

Abstract:

ERCP is one of the most invasive endoscopic procedures with a complication risk of up to 10 percent. Post-ERCP pancreatitis is dominating. The possibilities to avoid post-ERCP Pancreatitis, especially NSAR administration and pancreatic stents are discussed.

Schlüsselwörter

ERCP - Sphinkterotomie - Komplikation - Pankreatitis - Vermeidung

Key words

ERCP - sphincterotomy - complication pancreatitis - prevention

Full Text

References

Literatur
1 Rabenstein T, Hahn EG. Post-ERCP pancreatitis: new momentum. Endoscopy 2002; 34: 325-329 . Review
2 Cheon YK, Cho KB, Watkins JL et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc 2007; 66: 1126-1132
3 Abdel Aziz AM, Lehman GA. Pancreatitis after endoscopic retrograde cholangio-pancreatography. World J Gastroenterol 2007; 13: 2655-2668
4 Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335: 909-918
5 Rabenstein T, Schneider HT, Nicklas M et al. The impact of skill and experience of the endoscopist on the outcome of endoscopic sphincterotomy. Gastrointest Endosc 1999; 50: 628-636
6 Rabenstein T, Roggenbuck S, Framke B et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP?. Gastrointest Endosc 2002; 55: 476-483
7 Rabenstein T, Fischer B, Wiessner V et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 59: 606-613
8 Andriulli A, Clemente R, Solmi L et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56 (04) 488-495
9 Zheng M, Chen Y, Yang X et al. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2007; 7: 6
10 Chen S, Shi H, Zou X et al. Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor’s New Clothes or Aladdin’s Magic Lamp?. Pancreas 2010; 39 (08) 1231-1237
11 Seta T, Nogucki Y. Protease inhibitors for preventing complications associated with ERCP: an updated meta-analysis. Gastrointest Endosc 2011; 73: 700-706
12 Yoo KS, Huh KR, Kim KO et al. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial. Pancreas 2011; 40: 181-186
13 Park KT, Kang DH, Choi CW et al. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?. Pancreas 2011; 40: 1215-1259
14 Chen B, Fan T, Wang CH. A meta-analysis for the effect of prophylactic GTN on the incidence of post-ERCP pancreatitis and on the successful rate of cannulation of bile ducts. BMC Gastroenterol 2010; 10: 85
15 Bai Y, Xu C, Yang X et al. Glyceryl trinitrate for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a meta-analysis of randomized, double-blind, placebo-controlled trials. Endoscopy 2009; 41: 690-695
16 Pezzilli R, Morselli-Labate AM, Corinaldesi R. NSAIDs and Acute Pancreatitis: A Systematic Review. Pharmaceuticals 2010; 3: 558-571
17 Murray B, Carter R, Imrie C et al. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124: 1786-1791
18 Elmunzer BJ, Scheiman JM, Lehman GA et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-1422
19 Dumonceau JM, Andriulli A, Deviere J et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy 2010; 42: 503-515
20 Mazaki T, Masuda H, Takayama T. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: a systematic review and meta-analysis. Endoscopy 2010; 42: 842-853
21 Sofuni A, Magucki H, Mukai T et al. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopicretrograde cholangiopancreatography pancreatitis in high-risk patients. Clin Gastroenterol Hepatol 2011; 9: 851-858
22 Choudhary A, Bechtold ML, Arif M et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73: 275-282
23 Rabenstein T, Ruppert T, Schneider HT et al. Benefits and risks of needle-knife papillotomy. Gastrointest Endosc 1997; 46: 207-211
24 Rabenstein T, Schneider HT, Hahn EG et al. 25 years of endoscopic sphincterotomy in Erlangen: assessment of experience in the treatment of 3498 patients. Endoscopy 1998; 30 (Suppl. 02) A194-A201
25 Cennamo V, Fuccio L, Zagari RM et al. Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials. Endoscopy 2010; 42: 381-388
26 Gong B, Hao L, Bie L et al. Does precut technique improve selective bile duct cannulation or increase post-ERCP pancreatitis rate? A meta-analysis of randomized controlled trials. Surg Endosc 2010; 24: 2670-2680